REstore physiological Sleep with The Orexin Receptor antagonist Almorexant

Trial Profile

REstore physiological Sleep with The Orexin Receptor antagonist Almorexant

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2011

At a glance

  • Drugs Almorexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Acronyms RESTORA
  • Most Recent Events

    • 28 Jan 2011 Status changed from planning to discontinued, according to a GlaxoSmithKline and Acetelion joint media release
    • 23 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top